Cosmo Metals Limited

CMO

Cosmo Metals Ltd. engages in the metal exploration business. The firm is focused on the advancement of its flagship Mt Venn, Winchester and Eastern Mafic projects in the underexplored Yamarna Belt, in the Eastern Goldfields region of Western Australia. Its projects in the Yamarna Region are located approximately 130 kilometers (km) east of Laverton in the Eastern Goldfields District of Western Australia. The Company’s Yamarna landholding immediately west of the 6.7Moz Gruyere gold mine comprises nine granted exploration licenses, two prospecting leases and two exploration license applications in three separate areas. The Winchester exploration area is located to the north of the Yamarna exploration area and consists of two tenements covering 91 square kilometers (km2). The company also has two other tenement applications in the southern Wheatbelt region of Western Australia. The Pingrup applications E70/5955 (6 blocks) and E70/5956 (16 blocks) overlie farmland south of Lake Grace.

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Neuren Pharmaceuticals Limited

NEU

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

VanEck MSCI International Sustainable Equity ETF

ESGI

ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.